[Articles] Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Journal content Created on 30 May 2026 The Lancet

• Details
• • All feed content
  • My feed content